Prospects of Tirzepatide in optimizing metabolic and bariatric surgery

doi:10.3877/cma.j.issn.2095-9605.2025.01.004

Abstract

Abstract:

Obesity and related metabolic diseases have become a global health challenge，Metabolic and bariatric surgery is currently one of the most effective treatments for obesity and type 2 diabetes.In recent years，with the deeper understanding of the mechanisms of metabolic surgery，more and more adjunctive therapies have been proposed to optimize the surgical outcome.Tirzepatide，a novel drug for the treatment of type 2 diabetes mellitus，has attracted widespread attention because of its excellent results in improving weight management and diabetes control.This article reviews the efficacy and safety of Tirzepatide and metabolic surgery in weight loss，as well as the potential application of Tirzepatide in metabolic surgery，discusses its role before and after surgery，and looks forward to future research directions，with the aim of providing new ideas and strategies for clinical treatment.

Key words: Obesity, Tirzepatide, Metabolic and bariatric surgery, Combined treatment

Mengdie Li, Yong Wang. Prospects of Tirzepatide in optimizing metabolic and bariatric surgery[J]. Chinese Journal of Obesity and Metabolic Diseases(Electronic Edition), 2025, 11(01): 26-32.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfpydxbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-9605.2025.01.004

https://zhfpydxbdzzz.cma-cmc.com.cn/EN/Y2025/V11/I01/26

References 58

［1］	中华人民共和国国家卫生健康委员会医政司.肥胖症中国诊疗指南（2024年版）［J］.中华消化外科杂志，2024，23（10）：1237-1260.
［2］	Bessesen DH，Van Gaal LF.Progress and challenges in anti-obesity pharmacotherapy ［J］.The lancet Diabetes & endocrinology，2018，6（3）：237-248.
［3］	曲伸，陆灏，宋勇峰.基于临床的肥胖症多学科诊疗共识（2021年版）［J/CD］.中华肥胖与代谢病电子杂志，2021，7（4）：211-226.
［4］	Coskun T，Sloop K W，Loghin C，et al.LY3298176，a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus：From discovery to clinical proof of concept ［J］.Molecular metabolism，2018，18：3-14.
［5］	Nauck MA，D'Alessio DA.Tirzepatide，a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction［J］.Cardiovasc Diabetol，2022，21（1）：169.
［6］	Campbell JE，Drucker DJ.Pharmacology，physiology，and mechanisms of incretin hormone action ［J］.Cell Metab，2013，17（6）：819-837.
［7］	Nauck MA，Meier JJ.The incretin effect in healthy individuals and those with type 2 diabetes：physiology，pathophysiology，and response to therapeutic interventions ［J］.The lancet Diabetes & endocrinology，2016，4（6）：525-536.
［8］	Regmi A，Aihara E，Christe ME，et al.Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor ［J］.Cell metabolism，2024，36（7）：1534-1549.e7.
［9］	Forzano I，Varzideh F，Avvisato R，et al.Tirzepatide：A systematic update ［J］.International journal of molecular sciences，2022，23（23）：14631.
［10］	Aronne LJ，Sattar N，Horn DB，et al.Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity：The SURMOUNT-4 randomized clinical trial ［J］.Jama，2024，331（1）：38-48.
［11］	Moreira CG，Russell R，Mishra AA，et al.bacterial adrenergic sensors regulate virulence of enteric pathogens in the gut ［J］.mBio，2016，7（3）：e00826.
［12］	Valentí V，Cienfuegos JA，Becerril Mañas S，et al.Mechanism of bariatric and metabolic surgery：beyond surgeons，gastroenterologists and endocrinologists ［J］.Revista espanola de enfermedades digestivas，2020，112（3）：229-233.
［13］	Coluzzi I，Raparelli L，Guarnacci L，et al.Food intake and changes in eating behavior after laparoscopic sleeve gastrectomy ［J］.Obesity surgery，2016，26（9）：2059-2067.
［14］	Dischinger U，Kötzner L，Kovatcheva-Datchary P，et al.Hypothalamic integrity is necessary for sustained weight loss after bariatric surgery：A prospective，cross-sectional study ［J］.Metabolism：clinical and experimental，2023，138：155341.
［15］	Schauer PR，Bhatt DL，Kashyap SR.Bariatric surgery or intensive medical therapy for diabetes after 5 years ［J］.The New England journal of medicine，2017，376（20）：1997.
［16］	Salminen P，Grönroos S，Helmiö M，et al.Effect of laparoscopic sleeve gastrectomy vs roux-en-y gastric bypass on weight loss，comorbidities，and reflux at 10 years in adult patients with obesity：The SLEEVEPASS randomized clinical trial ［J］.JAMA Surg，2022，157（8）：656-666.
［17］	Albaugh VL，He Y，Münzberg H，et al.Regulation of body weight：Lessons learned from bariatric surgery ［J］.Molecular metabolism，2023，68：101517.
［18］	Dang JT，Mocanu V，Park H，et al.Roux-en-Y gastric bypass and sleeve gastrectomy induce substantial and persistent changes in microbial communities and metabolic pathways ［J］.Gut Microbes，2022，14（1）：2050636.
［19］	Le Chatelier E，Nielsen T，Qin J，et al.Richness of human gut microbiome correlates with metabolic markers ［J］.Nature，2013，500（7464）：541-546.
［20］	Liou AP，Paziuk M，Luevano JM，Jr.，et al.Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity ［J］.Science translational medicine，2013，5（178）：178ra41.
［21］	Rosenstock J，Wysham C，Frías JP，et al.Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes （SURPASS-1）：a double-blind，randomised，phase 3 trial ［J］.Lancet （London，England），2021，398（10295）：143-155.
［22］	Frías JP，Davies MJ，Rosenstock J，et al.Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes ［J］.The New England journal of medicine，2021，385（6）：503-515.
［23］	Ludvik B，Giorgino F，Jódar E，et al.Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes （SURPASS-3）：a randomised，open-label，parallel-group，phase 3 trial ［J］.Lancet（London，England），2021，398（10300）：583-598.
［24］	Del Prato S，Kahn SE，Pavo I，et al.Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk （SURPASS-4）：a randomised，open-label，parallel-group，multicentre，phase 3 trial ［J］.Lancet （London，England），2021，398（10313）：1811-1824.
［25］	Dahl D，Onishi Y，Norwood P，et al.Effect of subcutaneous Tirzepatide vs Placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes：The SURPASS-5 randomized clinical trial ［J］.Jama，2022，327（6）：534-545.
［26］	Jiang Y，Zhu H，Gong F.Why does GLP-1 agonist combined with GIP and/or GCG agonist have greater weight loss effect than GLP-1 agonist alone in obese adults without type 2 diabetes？［J］.Diabetes，obesity & metabolism，2025，27（3）：1079-1095.
［27］	Heise T，DeVries J H，Urva S，et al.Tirzepatide reduces appetite，energy intake，and fat mass in people with type 2 diabetes ［J］.Diabetes care，2023，46（5）：998-1004.
［28］	Jastreboff AM，Aronne LJ，Ahmad NN，et al.Tirzepatide once weekly for the treatment of obesity ［J］.The New England journal of medicine，2022，387（3）：205-216.
［29］	Müllertz ALO，Sandsdal RM，Jensen SBK，et al.Potent incretinbased therapy for obesity：A systematic review and meta-analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference，and safety ［J］.Obesity reviews，2024，25（5）：e13717.
［30］	孙雪，宋伟东，任淞泽，等.替西帕肽用于2型糖尿病治疗的研究进展［J］.中国医药科学［J］.2024，14（08）：33-6+77.
［31］	Sohal A，Casanova L，Kowdley KV.A Rare Case of Tirzepatide-Induced Hepatotoxicity ［J］.ACG Case Rep J，2024，11（10）：e01484.
［32］	Hartman ML，Sanyal AJ，Loomba R，et al.Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes ［J］.Diabetes care，2020，43（6）：1352-1355.
［33］	Lin F，Yu B，Ling B，et al.Weight loss efficiency and safety of tirzepatide：A systematic review ［J］.PloS one，2023，18（5）：e0285197.
［34］	Frias JP，Nauck MA，Van J，et al.Efficacy and tolerability of tirzepatide，a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes：A 12-week，randomized，double-blind，placebo-controlled study to evaluate different dose-escalation regimens ［J］.Diabetes，obesity & metabolism，2020，22（6）：938-946.
［35］	Jakobsen GS，Småstuen MC，Sandbu R，et al.Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities ［J］.Jama，2018，319（3）：291-301.
［36］	Ghiassi S，Morton JM.Safety and efficacy of bariatric and metabolic surgery ［J］.Current obesity reports，2020，9（2）：159-164.
［37］	O'Brien PE，Hindle A，Brennan L，et al.Long-term outcomes after bariatric surgery：a systematic review and meta-analysis of weight loss at 10 or more years for all bariatric procedures and a singlecentre review of 20-year outcomes after adjustable gastric banding ［J］.Obesity surgery，2019，29（1）：3-14.
［38］	Rubino F，Nathan DM，Eckel RH，et al.Metabolic surgery in the treatment algorithm for type 2 diabetes：a joint statement by international diabetes organizations ［J］.Obesity surgery，2017，27（1）：2-21.
［39］	Schauer PR，Bhatt DL，Kirwan JP，et al.Bariatric surgery versus intensive medical therapy for diabetes - 5-year outcomes ［J］.The New England journal of medicine，2017，376（7）：641-651.
［40］	Sjöström L，Lindroos AK，Peltonen M，et al.Lifestyle，diabetes，and cardiovascular risk factors 10 years after bariatric surgery ［J］.The New England journal of medicine，2004，351（26）：2683-2693.
［41］	Lee WJ，Chong K，Ser KH，et al.Gastric bypass vs sleeve gastrectomy for type 2 diabetes mellitus：a randomized controlled trial ［J］.Arch Surg，2011，146（2）：143-148.
［42］	McGlone ER，Carey I，Veličković V，et al.Bariatric surgery for patients with type 2 diabetes mellitus requiring insulin：Clinical outcome and cost-effectiveness analyses ［J］.PLoS medicine，2020，17（12）：e1003228.
［43］	Sandoval DA，Patti ME.Glucose metabolism after bariatric surgery：implications for T2DM remission and hypoglycaemia ［J］.Nature reviews Endocrinology，2023，19（3）：164-176.
［44］	van Veldhuisen SL，Gorter TM，van Woerden G，et al.Bariatric surgery and cardiovascular disease：a systematic review and metaanalysis ［J］.European heart journal，2022，43（20）：1955-1969.
［45］	Cohen RV，Pereira TV，Aboud CM，et al.Effect of gastric bypass vs best medical treatment on early-stage chronic kidney disease in patients with type 2 diabetes and obesity：A randomized clinical trial［J］.JAMA Surg，2020，155（8）：e200420.
［46］	Lee Y，Doumouras AG，Yu J，et al.Laparoscopic sleeve gastrectomy versus laparoscopic roux-en-y gastric bypass：A systematic review and meta-analysis of weight loss，comorbidities，and biochemical outcomes from randomized controlled trials ［J］.Annals of surgery，2021，273（1）：66-74.
［47］	王兵，王存川.减重代谢手术治疗肥胖合并阻塞性睡眠呼吸暂停——减重代谢外科视角［J］.中华肥胖与代谢病电子杂志，2018，4（02）：65-68.
［48］	Daigle CR，Brethauer SA，Tu C，et al.Which postoperative complications matter most after bariatric surgery？ Prioritizing quality improvement efforts to improve national outcomes ［J］.Surgery for obesity and related diseases，2018，14（5）：652-657.
［49］	Pareek M，Schauer PR，Kaplan LM，et al.Metabolic surgery：weight loss，diabetes，and beyond ［J］.J Am Coll Cardiol，2018，71（6）：670-687.
［50］	Qin W，Yang J，Ni Y，et al.Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo：An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial ［J］.Endocrine，2024，86（1）：70-84.
［51］	Sun Y，Liu B，Smith JK，et al.Association of preoperative body weight and weight loss with risk of death after bariatric surgery ［J］.JAMA network open，2020，3（5）：e204803.
［52］	Ard JD，Beavers DP，Hale E，et al.Use of phentermine-topiramate extended release in combination with sleeve gastrectomy in patients with BMI 50 kg/m（2） or more ［J］.Surgery for obesity and related disease，2019，15（7）：1039-1043.
［53］	Jamal M，Alhashemi M，Dsouza C，et al.Semaglutide and Tirzepatide for the management of weight recurrence after sleeve gastrectomy：a retrospective cohort study ［J］.Obesity surgery，2024，34（4）：1324-1332.
［54］	Buckley A，Suliman S，Allum M，et al.Real world use of tirzepatide in the treatment of type 2 diabetes in an Arab population ［J］.Diabetes，obesity & metabolism，2024，26（8）：3381-3391.
［55］	Stortz E，Lawler H.Tirzepatide improves early dumping syndrome and glucose nadir in postbariatric hypoglycemia after sleeve gastrectomy ［J］.JCEM case reports，2024，2（11）：luae194.
［56］	Freckmann G，Hagenlocher S，Baumstark A，et al.Continuous glucose profiles in healthy subjects under everyday life conditions and after different meals ［J］.Journal of diabetes science and technology，2007，1（5）：695-703.
［57］	Stahl JM，Malhotra S.Obesity Surgery Indications and Contraindications ［M］.StatPearls.Treasure Island （FL） ineligible companies.Disclosure：Sandeep Malhotra declares no relevant financial relationships with ineligible companies.； StatPearls Publishing Copyright © 2024，StatPearls Publishing LLC.2024.
［58］	Jalleh RJ，Rayner CK，Hausken T，et al.Gastrointestinal effects of GLP-1 receptor agonists：mechanisms，management，and future directions ［J］.The lancet Gastroenterology & hepatology，2024，9（10）：957-964.

[1]	Yun Xiang, You Lu, Fan Yang. Current research status of correlation between per-and polyfluoroalkyl substances exposure and childhood obesity [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2024, 20(05): 569-574.
[2]	Ka Teng Chan, Meijun Du, Bing Shi, Hanyao Huang. The impact of maternal systemic diseases on the incidence of cleft lip and palate in newborns [J]. Chinese Journal of Stomatological Research(Electronic Edition), 2024, 18(04): 262-268.
[3]	Society for Integrated Health of Metabolic and Bariatric Surgery Chinese, Society for Metabolic and Bariatric Surgery Chinese, Obesity and Metabolic Surgery Collaborative Chinese. Chinese expert consensus on medical knowledge dissemination in metabolic and bariatric surgery（2024 edition） [J]. Chinese Archives of General Surgery(Electronic Edition), 2025, 19(01): 1-8.
[4]	Jiajie Lu, Shuai Yan, Weihua Cai, Jinzhu Wu. Analysis of the related factors of weight rebound after sleeve gastrectomy in patients with obesity [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(03): 349-352.
[5]	Lixia Zhao, Chunxia Wang, Yifeng Chen, Dongping Hu, Weisheng Zhang, Tao Wang, Honglai Zhang. Effects of visceral obesity on early complications after laparoscopic radical resection for rectal cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(01): 35-39.
[6]	Lingkai Meng, Dayong Li, Ning Wang, Guiming Wang, Bingnan Zhang, Ruotong Li, Lifeng Pan. Effect and mechanism of sleeve gastrectomy on obese rats with type 2 diabetes mellitus [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(06): 638-642.
[7]	Meng Li, La Jiang, Lei Dong, Qing Wu, Ben Li Jia. Clinical study of laparoscopic gastric sleeve resection in the treatment of obesity complicated with type 2 diabetes mellitus and fatty pancreas [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(05): 554-557.
[8]	Shunfu Ji, Xiaoyan Tang, Jin Xu. Application of expanding retrogastric space in obese patients during laparoscopic radical resection of proximal gastric cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(04): 393-396.
[9]	Qi Han, Maimaitiming Maimaitiaili, Xudong Huang, Hao Wang, Abudureyimu Kelimu, Aili Aikebaier. Mid-term efficacy analysis of laparoscopic sleeve gastrectomy or combined with hiatal hernia repair in the treatment of obesity with gastroesophageal reflux disease [J]. Chinese Journal of Hernia and Abdominal Wall Surgery(Electronic Edition), 2024, 18(05): 501-506.
[10]	Jian Liu, Xiaobo Yang, Junjian He, Miao Wu. Application of electric hook in three-port laparoscopic sleeve gastrectomy [J]. Chinese Journal of Laparoscopic Surgery(Electronic Edition), 2024, 17(06): 363-364.
[11]	Haowen Xie, Jianying Ding, Xiaoxia Liu, Yi Feng, Jing Yao. Effect of paravertebral nerve block on intraoperative blood flow，postoperative stress and rehabilitation quality of obese patients undergoing minimally invasive gastrectomy [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2024, 14(06): 569-573.
[12]	Xing Wang, Yuan Chen, , Wusman Rezi Wan Guli, Yanying Guo. Co-pathogenic genes and potential common molecular mechanisms of type 2 diabetes mellitus, obesity, nonalcoholic steatohepatitis, and polycystic ovary syndrome [J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(05): 481-490.
[13]	Ruimin Zhang, Hongmei Zhu, Yanjun Liu. Current status and prospects of clinical research on metabolic and bariatric surgery in China [J]. Chinese Journal of Obesity and Metabolic Diseases(Electronic Edition), 2025, 11(01): 1-10.
[14]	Yuan Zhang, Zhongyang Zhang, Jiebin Xie, Dianyuan Liang, Zhenghang Yu, Yixing Ren. The mechanism of action and research progress of novel anti-obesity medications [J]. Chinese Journal of Obesity and Metabolic Diseases(Electronic Edition), 2025, 11(01): 11-18.
[15]	Wenbo Wang, Yaoquan Cao, Liyong Zhu. Recent developments in novel anti-obesity medications [J]. Chinese Journal of Obesity and Metabolic Diseases(Electronic Edition), 2025, 11(01): 19-25.

Please choose a citation manager

Content to export